Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Rotavirus Vaccination Recommended for Infants in Germany, Slight Intussusception Risk

By Deutsches Ärzteblatt International | May 25, 2017

Rotavirus vaccination in infants and young children.

Rotaviruses (RV) are the commonest cause of diarrhea in infants and young children worldwide. To protect against rotavirus infection, in 2013 the Standing Committee on Vaccination (STIKO, Ständige Impfkommission) in Germany recommended rotavirus vaccination for all infants. According to current studies, the efficacy of the vaccines in use may be regarded as very high.

Vaccinating babies and young children against rotaviruses is associated with a slight rise in the risk of intussusception. The risk exists for a period of up to a week after the first dose of vaccine has been given. “Intussusception” is the name given to the condition where one part of the intestine folds into another part. A child with an intussusception requires immediate diagnosis and treatment, which is usually conservative. However, the intussusception risk is much lower if the vaccination, which is carried out in a series of two or three doses, is started when the child is aged between 6 and 12 weeks, as recommended by STIKO. This is the conclusion reached by Judith Koch and her co-authors on the basis of a systematic literature review and meta-analysis in the current issue of Deutsches Ärzteblatt International (Dtsch Arztbl Int 2017; 114: 255-62).

Every year, around the world an estimated 453 000 children die before the age of 5 from the effects of a rotavirus infection. Before the introduction of vaccination, rotavirus-related gastroenteritis was the commonest notifiable disease of children in this age group in Germany. About half of these children needed hospital treatment.

In their review article in Deutsches Ärzteblatt International, the authors point out that if vaccination is carried out at the right time, the increase in intussusception risk is only marginal. Their analysis shows that without rotavirus vaccination, one child in 5208 will suffer intussusception during the first 3 months of life, whereas with vaccination the figure is one child in 4785. Parents should be informed of this slightly increased risk during their appointment with the doctor. However, currently as many as 11.2 percent of infants receive their first dose of vaccine when they are past the age of 3 months, which is associated with a somewhat greater risk of intussusception.

(Source: EurekAlert!)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE